399 related articles for article (PubMed ID: 27942208)
1. Three-minute constant rate step test for detecting exertional dyspnea relief after bronchodilation in COPD.
Borel B; Wilkinson-Maitland CA; Hamilton A; Bourbeau J; Perrault H; Jensen D; Maltais F
Int J Chron Obstruct Pulmon Dis; 2016; 11():2991-3000. PubMed ID: 27942208
[TBL] [Abstract][Full Text] [Related]
2. Relieving exertional dyspnea during the 3-min constant speed shuttle test in patients with COPD with indacaterol/glycopyrronium
Beaulieu J; Jensen D; O'Donnell DE; Brouillard C; Tracey L; Vincent S; Nadreau É; Bernard E; Bernard S; Maltais F
Ther Adv Respir Dis; 2020; 14():1753466620939507. PubMed ID: 32663102
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of ipratropium bromide/salbutamol sulphate administered in a hydrofluoroalkane metered-dose inhaler for the treatment of COPD.
Bhattacharya A; Bhargava S; Singh V; Talwar D; Whig J; Rebello J; Purandare S; Gogtay J
Int J Chron Obstruct Pulmon Dis; 2016; 11():1469-76. PubMed ID: 27418820
[TBL] [Abstract][Full Text] [Related]
4. Detecting improvements in dyspnea in COPD using a three-minute constant rate shuttle walking protocol.
Sava F; Perrault H; Brouillard C; Darauay C; Hamilton A; Bourbeau J; Maltais F
COPD; 2012 Aug; 9(4):395-400. PubMed ID: 22509905
[TBL] [Abstract][Full Text] [Related]
5. Bronchodilator response of advanced lung function parameters depending on COPD severity.
Jarenbäck L; Eriksson G; Peterson S; Ankerst J; Bjermer L; Tufvesson E
Int J Chron Obstruct Pulmon Dis; 2016; 11():2939-2950. PubMed ID: 27932874
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study.
LaForce C; Feldman G; Spangenthal S; Eckert JH; Henley M; Patalano F; D'Andrea P
Int J Chron Obstruct Pulmon Dis; 2016; 11():1233-43. PubMed ID: 27354782
[TBL] [Abstract][Full Text] [Related]
7. Bronchodilator reversibility in patients with COPD revisited: short-term reproducibility.
Pascoe S; Wu W; Zhu CQ; Singh D
Int J Chron Obstruct Pulmon Dis; 2016; 11():2035-40. PubMed ID: 27621609
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage I COPD.
O'Donnell DE; Laveneziana P; Ora J; Webb KA; Lam YM; Ofir D
Thorax; 2009 Mar; 64(3):216-23. PubMed ID: 19052054
[TBL] [Abstract][Full Text] [Related]
9. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease.
O'Donnell DE; Lam M; Webb KA
Am J Respir Crit Care Med; 1998 Nov; 158(5 Pt 1):1557-65. PubMed ID: 9817708
[TBL] [Abstract][Full Text] [Related]
10. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate.
Mahler DA; Waterman LA; Ward J; Gifford AH
J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):103-9. PubMed ID: 23745526
[TBL] [Abstract][Full Text] [Related]
11. The role of domiciliary nebulizers in managing patients with severe COPD.
Eiser N; Angus K; McHale S
Respir Med; 2001 Apr; 95(4):265-74. PubMed ID: 11316108
[TBL] [Abstract][Full Text] [Related]
12. Walking exercise response to bronchodilation in mild COPD: a randomized trial.
Gagnon P; Saey D; Provencher S; Milot J; Bourbeau J; Tan WC; Martel S; Maltais F
Respir Med; 2012 Dec; 106(12):1695-705. PubMed ID: 22999808
[TBL] [Abstract][Full Text] [Related]
13. Acute bronchodilator therapy does not reduce wasted ventilation during exercise in COPD.
Elbehairy AF; Webb KA; Laveneziana P; Domnik NJ; Neder JA; O'Donnell DE;
Respir Physiol Neurobiol; 2018 Jun; 252-253():64-71. PubMed ID: 29578103
[TBL] [Abstract][Full Text] [Related]
14. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial.
Beeh KM; Singh D; Di Scala L; Drollmann A
Int J Chron Obstruct Pulmon Dis; 2012; 7():503-13. PubMed ID: 22973092
[TBL] [Abstract][Full Text] [Related]
15. The effects of extrafine beclometasone/formoterol (BDP/F) on lung function, dyspnea, hyperinflation, and airway geometry in COPD patients: novel insight using functional respiratory imaging.
De Backer J; Vos W; Vinchurkar S; Van Holsbeke C; Poli G; Claes R; Salgado R; De Backer W
J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):88-99. PubMed ID: 25004168
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of tiotropium and olodaterol combination therapy on dynamic lung hyperinflation evaluated by hyperventilation in COPD: an open-label, comparative before and after treatment study.
Kawachi S; Fujimoto K
Int J Chron Obstruct Pulmon Dis; 2019; 14():1167-1176. PubMed ID: 31213796
[No Abstract] [Full Text] [Related]
17. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
[TBL] [Abstract][Full Text] [Related]
18. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
[TBL] [Abstract][Full Text] [Related]
19. Effects of pharmacologic treatment based on airflow limitation and breathlessness on daily physical activity in patients with chronic obstructive pulmonary disease.
Minakata Y; Morishita Y; Ichikawa T; Akamatsu K; Hirano T; Nakanishi M; Matsunaga K; Ichinose M
Int J Chron Obstruct Pulmon Dis; 2015; 10():1275-82. PubMed ID: 26170656
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
